The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma

CONCLUSIONSThe addition of cixutumumab or temozolomide to intensive multiagent chemotherapy for metastatic RMS was safe and feasible. Neither agent improved outcome compared with the same chemotherapy that was used on ARST0431.

Source: Cancer - October 23, 2018 Category: Cancer & Oncology Authors: Suman Malempati, Brenda J. Weigel, Yueh ‐Yun Chi, Jing Tian, James R. Anderson, David M. Parham, Lisa A. Teot, David A. Rodeberg, Torunn I. Yock, Barry L. Shulkin, Sheri L. Spunt, William H. Meyer, Douglas S. Hawkins Tags: Original Article Source Type: research